These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 19195431)
1. [Tenofovir: pharmacology and interactions]. Azanza JR; García Quetglas E; Sádaba B; Gómez-Giu A Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():2-6. PubMed ID: 19195431 [TBL] [Abstract][Full Text] [Related]
2. [Clinical data I. Clinical experience with tenofovir in combination with nonnucleoside analogue transcriptase inhibitors]. Bernardino de la Serna JI; Mora Rillo M; Arribas López JR Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():7-12. PubMed ID: 19195432 [TBL] [Abstract][Full Text] [Related]
3. Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection. Fung HB; Stone EA; Piacenti FJ Clin Ther; 2002 Oct; 24(10):1515-48. PubMed ID: 12462284 [TBL] [Abstract][Full Text] [Related]
4. [Clinical data II. Clinical experience of tenofovir DF in combination with protease inhibitors]. Pulido F; Fiorante S Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():13-8. PubMed ID: 19195433 [TBL] [Abstract][Full Text] [Related]
7. Tenofovir disoproxil fumarate for the treatment of HIV infection. Pham PA; Gallant JE Expert Opin Drug Metab Toxicol; 2006 Jun; 2(3):459-69. PubMed ID: 16863446 [TBL] [Abstract][Full Text] [Related]
12. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Kiser JJ; Carten ML; Aquilante CL; Anderson PL; Wolfe P; King TM; Delahunty T; Bushman LR; Fletcher CV Clin Pharmacol Ther; 2008 Feb; 83(2):265-72. PubMed ID: 17597712 [TBL] [Abstract][Full Text] [Related]
13. Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection. Lyseng-Williamson KA; Reynolds NA; Plosker GL Drugs; 2005; 65(3):413-32. PubMed ID: 15669881 [TBL] [Abstract][Full Text] [Related]
14. Protease inhibitors and non-nucleoside reverse transcriptase inhibitors have a comparable effect on the CD4 cell change after switching to tenofovir-based regimens. van Leth F; Prins JM; Lange JM; Geerlings SE AIDS; 2005 Oct; 19(15):1722-3. PubMed ID: 16184059 [No Abstract] [Full Text] [Related]
16. Intracellular nucleotide levels during coadministration of tenofovir disoproxil fumarate and didanosine in HIV-1-infected patients. Hawkins T; Veikley W; Durand-Gasselin L; Babusis D; Reddy YS; Flaherty JF; Ray AS Antimicrob Agents Chemother; 2011 Apr; 55(4):1549-55. PubMed ID: 21282432 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment. Kearney BP; Yale K; Shah J; Zhong L; Flaherty JF Clin Pharmacokinet; 2006; 45(11):1115-24. PubMed ID: 17048975 [TBL] [Abstract][Full Text] [Related]
18. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients. Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076 [TBL] [Abstract][Full Text] [Related]
19. [Tenofovir as a strategy to avoid or limit adverse effects]. Portilla J Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():19-24. PubMed ID: 19195434 [TBL] [Abstract][Full Text] [Related]
20. [Role of tenofovir in HIV and hepatitis C virus coinfection]. Tuma P; Vispo E; Barreiro P; Soriano V Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():31-7. PubMed ID: 19195436 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]